Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...

In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...